<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39239958</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Radially Emitting Diode Laser Closure of Transsphincteric Fistula-in-Ano.</ArticleTitle><Pagination><StartPage>1555</StartPage><EndPage>1563</EndPage><MedlinePgn>1555-1563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003501</ELocationID><Abstract><AbstractText Label="BACKGROUND">There has been a shift in the treatment of fistula-in-ano toward a focus on the preservation of continence while simultaneously eradicating the disease. The utilization of radially emitting diode laser catheters to ablate fistula tracks has been described since 2011, with heterogenous studies publishing success rates ranging from 20% to 89%.</AbstractText><AbstractText Label="OBJECTIVE">Present the authors' experience managing solitary transsphincteric fistulas of cryptoglandular origin with a radially emitting diode laser.</AbstractText><AbstractText Label="DESIGN">Prospective nonrandomized single center trial with 12-month follow-up.</AbstractText><AbstractText Label="SETTINGS">Quaternary referral academic health care center.</AbstractText><AbstractText Label="PATIENTS">Forty-six adults with transsphincteric fistula-in-ano.</AbstractText><AbstractText Label="INTERVENTIONS">All patients underwent radially emitting diode laser closure of fistula-in-ano.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Clinical healing and fistula recurrence.</AbstractText><AbstractText Label="RESULTS">Forty-six patients with a median age of 48 years (range, 26-85) underwent diode laser closure. Most were men (n = 28; 60%). Twenty-four patients (52%) had previous fistula repairs with a median of 1.5 (range, 1-7) repairs per patient. All were followed for 12 months. Successful closure after 1 laser treatment occurred in 43% of patients. Thirteen of 26 failure cases (50%) were able to undergo a delayed fistulotomy secondary to an anatomic change with the fistula becoming more superficial, moving out of the internal sphincter muscle after laser ablation, all of which healed. No patients experienced new or worsening (preexisting) fecal incontinence. Two patients (8%) continued treatment for abscesses/fistula branching. One patient (3%) experienced migration of the fistula from the base of the left labia to the introitus of the vagina and 1 experienced recurrence and worsening of their disease process with subsequent involvement of the coccyx (previous deep postanal space abscess).</AbstractText><AbstractText Label="LIMITATIONS">Limitations to our study include its nonrandomized prospective nature, single center and surgeon experience, and small patient sample size.</AbstractText><AbstractText Label="CONCLUSIONS">Radially emitting diode laser closure is a continence-preserving option to consider when treating transsphincteric fistula-in-ano. When the procedure fails, it does not fail poorly (open wounds, retracted flaps, incontinence, etc) and can be repeated. Complications can include abscess formation and fistula migration to adjacent anatomic locations (vagina). Even if unsuccessful, after treatment, the fistula can anatomically migrate distally, becoming more superficial and thus providing the opportunity to proceed with a delayed fistulotomy. See Video Abstract .</AbstractText><AbstractText Label="CIERRE DE FSTULA ANAL TRANSESFINTRICA CON LSER DE DIODO DE EMISIN RADIAL">ANTECEDENTES:Ha habido un cambio en el tratamiento de la f&#xed;stula anal hacia un enfoque en la preservaci&#xf3;n de la continencia y al mismo tiempo en la erradicaci&#xf3;n de la enfermedad. La utilizaci&#xf3;n de cat&#xe9;teres l&#xe1;ser de diodo de emisi&#xf3;n radial para extirpar los trayectos de las f&#xed;stulas se describe desde el 2011 y estudios heterog&#xe9;neos publican tasas de &#xe9;xito que oscilan entre el 20 y el 89%.OBJETIVO:Presentar nuestra experiencia en el manejo de f&#xed;stulas transesfinterianas solitarias de origen criptoglandular con l&#xe1;ser de diodo de emisi&#xf3;n radial.DISE&#xd1;O:Ensayo prospectivo, no aleatorizado, unic&#xe9;ntrico, con seguimiento de 12 meses.LUGARES:Centro de salud acad&#xe9;mico de referencia Cuaternario.PACIENTES:Cuarenta y seis adultos con f&#xed;stula anal transesfint&#xe9;rica.INTERVENCIONES:Todos se sometieron a cierre de f&#xed;stula anal con l&#xe1;ser de diodo de emisi&#xf3;n radial.MEDIDAS PRINCIPALES DEL RESULTADO:Curaci&#xf3;n cl&#xed;nica y recurrencia de la f&#xed;stula.RESULTADOS:Cuarenta y seis pacientes con una mediana de edad de 48 a&#xf1;os (rango, 26-85) se sometieron a cierre con l&#xe1;ser de diodo. La mayor&#xed;a eran hombres (n=28/60%). Veinticuatro (52%) hab&#xed;an tenido reparaciones previas de f&#xed;stulas con una mediana de 1,5 (rango, 1-7) reparaciones por paciente. Todos fueron seguidos durante 12 meses. El cierre exitoso despu&#xe9;s de un tratamiento con l&#xe1;ser se produjo en el 43%. Trece de 26 fracasos (50%) pudieron someterse a una fistulotom&#xed;a tard&#xed;a debido a un cambio anat&#xf3;mico en el que la f&#xed;stula se volvi&#xf3; m&#xe1;s superficial y sali&#xf3; del m&#xfa;sculo del esf&#xed;nter interno despu&#xe9;s de la ablaci&#xf3;n con l&#xe1;ser, y todas sanaron. Ning&#xfa;n paciente experiment&#xf3; incontinencia fecal nueva o que empeor&#xf3; (preexistente). Dos (8%) continuaron tratamiento por abscesos/ramificaci&#xf3;n de f&#xed;stulas. Una (3%) experiment&#xf3; migraci&#xf3;n de la f&#xed;stula desde la base de los labios izquierdos hasta el introito de la vagina y 1 experiment&#xf3; recurrencia y empeoramiento de su proceso patol&#xf3;gico con posterior afectaci&#xf3;n del c&#xf3;ccix (absceso previo en el espacio postanal profundo).LIMITACIONES:Las limitaciones de nuestro estudio incluyen su naturaleza prospectiva no aleatoria, la experiencia de un solo centro y del cirujano y el tama&#xf1;o peque&#xf1;o de la muestra de pacientes.CONCLUSIONES:El cierre con l&#xe1;ser de diodo de emisi&#xf3;n radial es una opci&#xf3;n para preservar la continencia a considerar cuando se trata la f&#xed;stula en el ano transesfint&#xe9;rica. Cuando el procedimiento fracasa, no fracasa mal (heridas abiertas, colgajos retra&#xed;dos, incontinencia, etc.), y puede repetirse. Las complicaciones pueden incluir formaci&#xf3;n de abscesos y migraci&#xf3;n de f&#xed;stulas a ubicaciones anat&#xf3;micas adyacentes (vagina). Incluso si no tiene &#xe9;xito, despu&#xe9;s del tratamiento la f&#xed;stula puede migrar anat&#xf3;micamente distal volvi&#xe9;ndose m&#xe1;s superficial y brindando as&#xed; la oportunidad de proceder con una fistulotom&#xed;a retrasada. (Traducci&#xf3;n-Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0003-1390-0019</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vierkant</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Kayleigh M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berndt</LastName><ForeName>Shannon R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054023" MajorTopicYN="Y">Lasers, Semiconductor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="Y">Laser Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cryptoglandular</Keyword><Keyword MajorTopicYN="N">Fistula-in-ano</Keyword><Keyword MajorTopicYN="N">Laser</Keyword><Keyword MajorTopicYN="N">Radially emitting diode</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39239958</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003501</ArticleId><ArticleId IdType="pii">00003453-990000000-00736</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, Garcia-Olmo D. An assessment of the incidence of fistula in ano in four countries of the European Union. Int J Colorectal Dis. 2007;22:1459&#x2013;1462.</Citation></Reference><Reference><Citation>Sanchez-Haro E, Vela E, Cleries M, et al. Clinical characterization of patients with anal fistula during follow-up of anorectal abscess: a large population-based study. Tech Coloproctol. 2023;27:897&#x2013;907.</Citation></Reference><Reference><Citation>Wilhelm A. A new technique for sphincter-preserving anal fistula repair using a novel radial emitting laser probe. Tech Coloproctol. 2011;15:445&#x2013;449.</Citation></Reference><Reference><Citation>D&#xf6;nmez T, Hatipo&#x11f;lu E. Closure of fistula tract with Filac TM laser as a sphincter preserving method in anal fistula treatment. Turk J Colorectal Dis. 2017;27:142&#x2013;147.</Citation></Reference><Reference><Citation>Wilhelm A, Fiebig A, Krawczak M. Five years of experience with the FiLaC TM laser for fistula-in-ano management: longterm follow-up from a single institution. Tech Coloproctol. 2017;21:269&#x2013;276.</Citation></Reference><Reference><Citation>Lauretta A, Falco N, Stocco E, Bellomo R, Infantino A. Anal fistula laser closure: the length of fistula is the achilles&#x2019; heel. Tech Coloproctol. 2018;22:933&#x2013;939.</Citation></Reference><Reference><Citation>Terzi MC, Agalar C, Habip S, Canda AE, Arslan NC, Obuz F. Closing perianal fistulas using a laser: long-term results in 103 patients. Dis Colon Rectum. 2018;61:599&#x2013;603.</Citation></Reference><Reference><Citation>De Hous N, de Gheldere C, Van den Broeck S, Komen N. FiLaC TM as a last, sphincter-preserving resort for complex perianal fistula. Tech Coloproctol. 2019;23:937&#x2013;938.</Citation></Reference><Reference><Citation>Marref I, Spindler L, Aubert M, et al. The optimal indication for FiLaC &#xae; is high trans-sphincteric fistula-in-ano: a prospective cohort of 69 consecutive patients. Tech Coloproctol. 2019;23:893&#x2013;897.</Citation></Reference><Reference><Citation>Stijns J, van Loon YT, Clermonts SHEM, G&#x4e7;ttgens KW, Wasowicz DK, Zimmerman DDE. Implementation of laser ablation of fistula tract (LAFT) for perianal fistulas: do the results warrant continued application of this technique? Tech Coloproctol. 2019;23:1127&#x2013;1132.</Citation></Reference><Reference><Citation>Alam A, Lin F, Fathallah N, et al. FiLaC &#xae; and Crohn&#x2019;s disease perianal fistulas: a pilot study of 20 consecutive patients. Tech Coloproctol. 2020;24:75&#x2013;78.</Citation></Reference><Reference><Citation>Brabender DE, Moran KL, Brady M, et al. Assessing the effectiveness of laser fistulectomy for anal fistula: a retrospective cohort study. Tech Coloproctol. 2020;24:1071&#x2013;1075.</Citation></Reference><Reference><Citation>de Bonnechose G, Lefevre JH, Aubert M, et al. Laser ablation of fistula tract (LAFT) and complex fistula-in-ano: &#x201c;the ideal indication&#x201d; is becoming clearer. Tech Coloproctol. 2020;24:695&#x2013;701.</Citation></Reference><Reference><Citation>Isik O, Gulcu B, Ozturk E. Long-term outcomes of laser ablation of fistula tract for fistula-in-ano: a considerable option in sphincter preservation. Dis Colon Rectum. 2020;63:831&#x2013;836.</Citation></Reference><Reference><Citation>Serin KR, Hacim NA, Karabay O, Terzi MC. Retrospective analysis of primary suturing of the internal orifice of perianal fistula during FiLaC procedure. Surg Laparosc Endosc Percutan Tech. 2020;30:266&#x2013;269.</Citation></Reference><Reference><Citation>Giamundo P, De Angelis M. Treatment of anal fistula with FiLaC( &#xae; ): results of a 10-year experience with 175 patients. Tech Coloproctol. 2021;25:941&#x2013;948.</Citation></Reference><Reference><Citation>Nordholm-Carstensen A, Perregaard H, Hagen KB, Krarup PM. Fistula laser closure (FiLaC TM ) for fistula-in-ano-yet another technique with 50% healing rates? Int J Colorectal Dis. 2021;36:1831&#x2013;1837.</Citation></Reference><Reference><Citation>Wolicki A, J&#xe4;ger P, Deska T, Senkal M. Sphincter-saving therapy for fistula-in-ano: long-term follow-up after FiLaC. Tech Coloproctol. 2021;25:177&#x2013;184.</Citation></Reference><Reference><Citation>Sluckin TC, Gispen WH, Jongenotter J, et al. Treatment of cryptoglandular fistulas with the fistula tract laser closure(FiLaC TM ) method in comparison with standard methods: first results of a multicenter retrospective comparative study in the Netherlands. Tech Coloproctol. 2022;26:797&#x2013;803.</Citation></Reference><Reference><Citation>Olajide TO, Bode CO. Closure of fistula-in-ano using a radial-emitting laser probe: initial experience in Lagos, Nigeria. J West Afr Coll Surg. 2023;13:101&#x2013;106.</Citation></Reference><Reference><Citation>Blanco Ter&#xe9;s L, Bermejo Marcos E, Cerd&#xe1;n Santacruz C, et al. FiLaC &#xae; procedure for highly selected anal fistula patients: indications, safety and efficacy from an observational study at a tertiary referral center. Rev Esp Enferm Dig. 2023;115:700&#x2013;706.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38319717</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Innate Immunity Activation in Newly Diagnosed Ileocolonic Crohn's Disease: A Cohort Study.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>692</EndPage><MedlinePgn>681-692</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003145</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies showed that early surgery for Crohn's disease leads to a lower recurrence rate. However, the underlying mechanism is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study aims to analyze the innate immunity microenvironment in ileal mucosa according to the duration of Crohn's disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Tertiary referral center for IBD surgery.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 88 consecutive patients with Crohn's disease undergoing ileocolonic resection were prospectively enrolled. Mucosal samples were obtained from both healthy and inflamed ileum. Data from a public data set were analyzed as an external validation cohort.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Neutrophil infiltration was evaluated by histological asessment and macrophage subpopulation was assessed by immunohistochemistry. Expressions of TLR2 , TLR4 , TLR5 , DEFB1 , DEFB4A , DEFB103 , DEFA5 , and DEFA6 were quantified by real-time quantitative polymerase chain reaction. Concentrations of BDNF, CCL-11, ICAM-1, IL-1A, IL-1&#x3b2;, IL-1RN, IL-12p40, IL-12p70, IL-15, IL-17A, IL-23A, MMP-3, CCL-3, KITLG, and VEGFA were determined with an immunometric assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neutrophil infiltration is inversely correlated with disease duration. DEFB4A mRNA expression tended to be higher in late-stage Crohn's disease ( p = 0.07). A higher number of macrophages expressed CD163 at low intensity in late-stage Crohn's disease ( p = 0.04). The concentration of IL-15 ( p = 0.02) and IL-23A ( p = 0.05) was higher in healthy ileal mucosa of early-stage patients. In the external cohort, expressions of DEFB1 ( p = 0.03), DEFB4A ( p = 0.01), IL-2 ( p = 0.04), and IL-3 ( p = 0.03) increased in patients with late-stage Crohn's disease.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">A relatively small number of patients, especially in the newly diagnosed group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In newly diagnosed Crohn's disease, high levels of IL-15 and IL-23 in healthy mucosa suggest that innate immunity is the starter of acute inflammation. Moreover, M2 macrophages increase in the healthy mucosa of patients with late-stage Crohn's disease, suggesting that reparative and profibrotic processes are predominant in the long term, and in this phase, anti-inflammatory therapy may be less efficient. See Video Abstract .</AbstractText><AbstractText Label="ACTIVACIN DE LA INMUNIDAD INNATA EN LA RECIENTEMENTE DIAGNOSTICADA ENFERMEDAD DE CROHN ILEOCLICA UN ESTUDIO DE COHORTE" NlmCategory="UNASSIGNED">ANTECEDENTES:Estudios recientes demostraron que la cirug&#xed;a temprana para la enfermedad de Crohn (EC) conduce a una menor tasa de recurrencia. Sin embargo, se desconoce el mecanismo subyacente.OBJETIVO:El estudio tiene como objetivo analizar el microambiente de la inmunidad innata en la mucosa ileal seg&#xfa;n la duraci&#xf3;n de la EC.DISE&#xd1;O:Un estudio de cohorte prospectivo.AJUSTES:Centro terciario de referencia para cirug&#xed;a de EII.PACIENTES:Fueron registrados de manera prospectiva y consecutiva 88 pacientes con EC sometidos a resecci&#xf3;n ileocol&#xf3;nica. Se obtuvieron muestras de mucosa ileal, tanto del &#xed;leon sano como del &#xed;leon inflamado. Los datos se analizaron como una cohorte de validaci&#xf3;n externa.PRINCIPALES MEDIDAS DE RESULTADO:Fueron evaluados la infiltraci&#xf3;n de neutr&#xf3;filos por histolog&#xed;a y la subpoblaci&#xf3;n de macr&#xf3;fagos por inmunohistoqu&#xed;mica. La expresi&#xf3;n de TLR2, TLR4, TLR5, DEFB1, DEFB4A, DEFB103, DEFA5 y DEFA6 fueron cuantificados mediante qPCR en tiempo real. Las concentraciones de BDNF, CCL-11, ICAM-1, IL-1A, IL-1B, IL-1RN, IL-12 p40, IL-12 p70, IL-15, IL-17A, IL-23A, MMP-3, CCL-3, KITLG, VEGFA se determinaron con ensayo inmunom&#xe9;trico.RESULTADOS:La infiltraci&#xf3;n de neutr&#xf3;filos se correlaciona inversamente con la duraci&#xf3;n de la enfermedad. La expresi&#xf3;n del ARNm de DEFB4A mostro una tendencia a ser mayor en la EC en etapa tard&#xed;a ( p = 0,07). Un mayor n&#xfa;mero de macr&#xf3;fagos expresaron CD163 a baja intensidad en la etapa tard&#xed;a ( p = 0,04). La concentraci&#xf3;n de IL15 ( p = 0,02) e IL23A ( p = 0,05) fue mayor en la mucosa ileal sana de pacientes en estadio temprano. En la cohorte externa, la expresi&#xf3;n de DEFB1 ( p = 0,03) y DEFB4A ( p = 0,01), IL2 ( p = 0,04) e IL3 ( p = 0,03) aument&#xf3; en pacientes en etapa tard&#xed;a.LIMITACIONES:Un n&#xfa;mero relativamente peque&#xf1;o de pacientes, especialmente en el grupo reci&#xe9;n diagnosticado.CONCLUSIONES:En la EC reci&#xe9;n diagnosticada, los altos niveles de IL-15 e IL-23 en la mucosa sana sugieren que la inmunidad innata es el promotor de la inflamaci&#xf3;n aguda. Adem&#xe1;s, los macr&#xf3;fagos M2 aumentan en la mucosa sana de pacientes con EC en etapa tard&#xed;a, lo que sugiere que los procesos reparadores y profibr&#xf3;ticos son predominantes a largo plazo y en esta fase, la terapia antiinflamatoria puede ser menos eficiente. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angriman</LastName><ForeName>Imerio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordignon</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotsafti</LastName><ForeName>Andromachi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mescoli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpa</LastName><ForeName>Melania</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruffolo</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fassan</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dei Tos</LastName><ForeName>Angelo Paolo</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Inc&#xe0;</LastName><ForeName>Renata</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savarino</LastName><ForeName>Edoardo Vincenzo</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zingone</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pucciarelli</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardini</LastName><ForeName>Romeo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castagliuolo</LastName><ForeName>Ignazio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Microbiology Unit, Department of Molecular Medicine (DMM), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpa</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0217-6523</Identifier><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019409">Interleukin-15</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.17</RegistryNumber><NameOfSubstance UI="D019278">Matrix Metalloproteinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051198">Toll-Like Receptor 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C406407">DEFB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023083">beta-Defensins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="Y">Intercellular Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019409" MajorTopicYN="N">Interleukin-15</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019278" MajorTopicYN="N">Matrix Metalloproteinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051198" MajorTopicYN="N">Toll-Like Receptor 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053759" MajorTopicYN="N">Interleukin-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023083" MajorTopicYN="Y">beta-Defensins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38319717</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003145</ArticleId><ArticleId IdType="pii">00003453-202405000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomoll&#xf3;n F, Dignass A, Annese V, et al.; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn&#x2019;s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3&#x2013;25.</Citation></Reference><Reference><Citation>Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL. Trends in the surgical management of Crohn&#x2019;s disease. J Gastrointest Surg. 2015;19:1862&#x2013;1868.</Citation></Reference><Reference><Citation>Ponsioen CY, de Groof EJ, Eshuis EJ, et al.; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn&#x2019;s disease: a randomized controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2:785&#x2013;792.</Citation></Reference><Reference><Citation>de Groof EJ, Stevens TW, Eshuis EJ, et al.; LIR!C study group. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn&#x2019;s disease: the LIR!C trial. Gut. 2019;68:1774&#x2013;1780.</Citation></Reference><Reference><Citation>Stevens TW, Haasnoot ML, D&#x2019;Haens GR, et al.; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn&#x2019;s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5:900&#x2013;907.</Citation></Reference><Reference><Citation>Kelm M, Anger F, Eichlinger R, et al. Early ileocecal resection is an effective therapy in isolated Crohn&#x2019;s disease. J Clin Med. 2021;10:731.</Citation></Reference><Reference><Citation>Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn&#x2019;s disease: a multicentre inception cohort study. Lancet. 2017;389:1710&#x2013;1718.</Citation></Reference><Reference><Citation>Forkel M, van Tol S, H&#xf6;&#xf6;g C, Micha&#xeb;lsson J, Almer S, Mj&#xf6;sberg J. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn&#x2019;s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67&#x2013;78.</Citation></Reference><Reference><Citation>Weizman OE, Adams NM, Schuster IS, et al. ILC1 confer early host protection at initial sites of viral infection. Cell. 2017;171:795&#x2013;808.e12.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation></Reference><Reference><Citation>Harvey RF, Bradshaw JM. A simple index of Crohn&#x2019;s disease activity. Lancet. 1980;1:514.</Citation></Reference><Reference><Citation>Tielbeek JAW, Ziech MLW, Li Z, et al. Evaluation of conventional, dynamic contrast-enhanced and diffusion-weighted MRI for quantitative Crohn&#x2019;s disease assessment with histopathology of surgical specimens. Eur Radiol. 2014;24:619&#x2013;629.</Citation></Reference><Reference><Citation>Verstockt S, De Hertogh G, Van der Goten J, et al. Gene and miRNA regulatory networks during different stages of Crohn&#x2019;s disease. J Crohns Colitis. 2019;13:916&#x2013;930.</Citation></Reference><Reference><Citation>Daperno M, D&#x2019;Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn&#x2019;s disease: the SES-CD. Gastrointest Endosc. 2004;60:505&#x2013;512.</Citation></Reference><Reference><Citation>Team RCR. A language and environment for statistical computing. https://www.R-project.org . Accessed May 15, 2023.</Citation></Reference><Reference><Citation>Magro F, Langner C, Driessen A, et al.; European Society of Pathology (ESP). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827&#x2013;851.</Citation></Reference><Reference><Citation>Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn&#x2019;s disease. Chem Immunol Allergy. 2005;86:42&#x2013;54.</Citation></Reference><Reference><Citation>Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn&#x2019;s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215&#x2013;223.</Citation></Reference><Reference><Citation>Aldhous MC, Noble CL, Satsangi J. Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One. 2009;4:e6285.</Citation></Reference><Reference><Citation>Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn&#x2019;s disease. Gut. 2008;57:903&#x2013;910.</Citation></Reference><Reference><Citation>Stebe-Frick S, Ostaff MJ, Stange EF, Malek NP, Wehkamp J. Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Sci Rep. 2018;8:12886.</Citation></Reference><Reference><Citation>Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in the colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:745&#x2013;752.</Citation></Reference><Reference><Citation>Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor-associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228:1404&#x2013;1412.</Citation></Reference><Reference><Citation>Franz&#xe8; E, Caruso R, Stolfi C, et al. Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. PLoS One. 2013;8:e69839.</Citation></Reference><Reference><Citation>Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.</Citation></Reference><Reference><Citation>Lourenssen SR, Blennerhassett MG. M2 macrophages and phenotypic modulation of intestinal smooth muscle cells characterize inflammatory stricture formation in rats. Am J Pathol. 2020;190:1843&#x2013;1858.</Citation></Reference><Reference><Citation>Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn&#x2019;s disease. Gut. 2013;62:852&#x2013;862.</Citation></Reference><Reference><Citation>Schulthess J, Meresse B, Ramiro-Puig E, et al. Interleukin-15-dependent NKp46+ innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity. 2012;37:108&#x2013;121.</Citation></Reference><Reference><Citation>Liu Z, Geboes K, Colpaert S, D&#x2019;Haens GR, Rutgeerts P, Ceuppens JL. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol. 2000;164:3608&#x2013;3615.</Citation></Reference><Reference><Citation>Bouchaud G, Mortier E, Flamant M, et al. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn&#x2019;s disease. Gastroenterology. 2010;138:2378&#x2013;2387.</Citation></Reference><Reference><Citation>Silva MA, Menezes J, Deslandres C, Seidman EG. Anti-inflammatory role of interleukin-15 in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2005;11:219&#x2013;230.</Citation></Reference><Reference><Citation>Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054&#x2013;1066.</Citation></Reference><Reference><Citation>Jowett GM, Norman MDA, Yu TTL, et al. ILC1 drive intestinal epithelial and matrix remodeling. Nat Mater. 2021;20:250&#x2013;259.</Citation></Reference><Reference><Citation>Grimm MC, Doe WF. Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macrophage inflammatory protein (MIP)-1&#x3b1;, MIP-1&#x3b2;, and &#x3b3;-interferon-inducible protein-10 by macrophages, lymphocytes, endothelial cells, and granulomas. Inflamm Bowel Dis. 1996;2:88&#x2013;96.</Citation></Reference><Reference><Citation>Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3&#x2013;10.</Citation></Reference><Reference><Citation>Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010;16:1808&#x2013;1813.</Citation></Reference><Reference><Citation>Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209&#x2013;217.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34711713</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Motivations and Barriers Toward Implementation of a Rectal Cancer Synoptic Operative Report: A Process Evaluation.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>360</EndPage><MedlinePgn>353-360</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002202</ELocationID><Abstract><AbstractText Label="BACKGROUND">The use of synoptic reporting has been shown to improve documentation of critical information and provide added value related to data access and extraction, data reliability, relevant detail, and completeness of information. Surgeon acceptance and adoption of synoptic reports has lagged behind other specialties.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to evaluate the process of implementing a synoptic operative report.</AbstractText><AbstractText Label="DESIGN">This study was a mixed-methods process evaluation including surveys and qualitative interviews.</AbstractText><AbstractText Label="SETTINGS">This study focused on colorectal surgery practices across the United States.</AbstractText><AbstractText Label="PATIENTS">Twenty-eight board-certified colorectal surgeons were included.</AbstractText><AbstractText Label="INTERVENTIONS">The synoptic operative report for rectal cancer was implemented.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Acceptability, feasibility, and usability were measured by Likert-type survey questions and followed up with individual interviews to elicit experiences with implementation as well as motivations and barriers to use.</AbstractText><AbstractText Label="RESULTS">Among all study participants, 28 surgeons completed the electronic survey (76% response rate) and 21 (57%) completed the telephone interview. Mean usability was 4.14 (range, 1-5; SE, 0.15), mean feasibility was 3.90 (SE, 0.15), and acceptability was 3.98 (SE, 0.18). Participants indicated that substantial administrative and technical support were necessary but not always available for implementation, and many were frustrated by the need to change their workflow.</AbstractText><AbstractText Label="LIMITATIONS">Most surgeon participants were male, white, had &gt;12 years in practice, and used Epic electronic medical record systems. Therefore, they may not represent the perspectives of all US colon and rectal surgeons. In addition, as the synoptic operative report is implemented more broadly across the United States, it will be important to consider variations in the process by electronic medical record system.</AbstractText><AbstractText Label="CONCLUSIONS">The synoptic operative report for rectal cancer was easy to implement and incorporate into workflow, in general, but surgeons remained concerned about additional burden without immediate and tangible value. Despite recognizing benefits, many participants indicated they only implemented the synoptic operative report because it was mandated by the National Accreditation Program for Rectal Cancer. See Video Abstract at http://links.lww.com/DCR/B735MOTIVACIONES Y BARRERAS HACIA LA IMPLEMENTACI&#xd3;N DE UN INFORME OPERATIVO SIN&#xd3;PTICO DE C&#xc1;NCER RECTAL: UNA EVALUACI&#xd3;N DEL PROCESOANTECEDENTES:Se ha demostrado que el uso de informes sin&#xf3;pticos mejora la documentaci&#xf3;n de informaci&#xf3;n cr&#xed;tica y proporciona un valor agregado relacionado con el acceso y extracci&#xf3;n de datos, la confiabilidad de los datos, los detalles relevantes y la integridad de la informaci&#xf3;n. La aceptaci&#xf3;n y adopci&#xf3;n de informes sin&#xf3;pticos por parte de los cirujanos se ha quedado rezagada con respecto a otras especialidades.OBJETIVO:Evaluar el proceso de implementaci&#xf3;n de un informe operativo sin&#xf3;ptico.DISE&#xd1;O:Evaluaci&#xf3;n de procesos de m&#xe9;todos mixtos que incluyen encuestas y entrevistas cualitativas.AJUSTES:Pr&#xe1;cticas de cirug&#xed;a colorrectal en los Estados Unidos.PACIENTES:Veintiocho cirujanos colorrectales certificados por la junta.INTERVENCIONES:Implementaci&#xf3;n del informe operatorio sin&#xf3;ptico de c&#xe1;ncer de recto.PRINCIPALES MEDIDAS DE RESULTADO:Aceptabilidad, viabilidad y usabilidad medidas por preguntas de encuestas tipo Likert y seguidas con entrevistas individuales para obtener experiencias con la implementaci&#xf3;n, as&#xed; como motivaciones y barreras para el uso.RESULTADOS:Entre todos los participantes del estudio, 28 cirujanos completaron la encuesta electr&#xf3;nica (tasa de respuesta del 76%) y 21 (57%) completaron la entrevista telef&#xf3;nica. La usabilidad media fue 4,14 (rango = 1-5, error est&#xe1;ndar (EE) = 0,15), la factibilidad media fue 3,90 (EE = 0,15) y la aceptabilidad fue 3,98 (EE = 0,18). Los participantes indicaron que se necesitaba un apoyo administrativo y t&#xe9;cnico sustancial, pero que no siempre estaba disponible para la implementaci&#xf3;n y muchos se sintieron frustrados por la necesidad de cambiar su flujo de trabajo.LIMITACIONES:La mayor&#xed;a de los cirujanos participantes eran hombres, blancos, ten&#xed;an &gt;12 a&#xf1;os en la pr&#xe1;ctica y usaban sistemas de registros m&#xe9;dicos electr&#xf3;nicos de Epic. Por lo tanto, es posible que no representen las perspectivas de todos los cirujanos de colon y recto de EE. UU. Adem&#xe1;s, a medida que el informe operativo sin&#xf3;ptico se implemente de manera m&#xe1;s amplia en los EE. UU., Ser&#xe1; importante considerar las variaciones en el proceso por sistema EMR.CONCLUSIONES:El informe quir&#xfa;rgico sin&#xf3;ptico para el c&#xe1;ncer de recto fue en general f&#xe1;cil de implementar e incorporar en el flujo de trabajo, pero los cirujanos segu&#xed;an preocupados por la carga adicional sin valor inmediato y tangible. A pesar de reconocer los beneficios, muchos participantes indicaron que solo implementaron el informe operativo sin&#xf3;ptico porque era un mandato del Programa Nacional de Acreditaci&#xf3;n para el C&#xe1;ncer de Recto. Consulte Video Resumen en http://links.lww.com/DCR/B735 (Traducci&#xf3;n-Dr. Xavier Delgadillo).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bidwell</LastName><ForeName>Serena S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>University of Michigan Medical School, Ann Arbor, Michigan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>S-SPIRE Center, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poles</LastName><ForeName>Gabriela C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Rochester Medical School, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staudenmayer</LastName><ForeName>Kristan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bereknyei Merrell</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S-SPIRE Center, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>S-SPIRE Center, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003107" MajorTopicYN="Y">Colorectal Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003144" MajorTopicYN="N">Communication Barriers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="Y">Digestive System Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004282" MajorTopicYN="Y">Documentation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="N">Health Information Exchange</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066231" MajorTopicYN="Y">Surgeons</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057188" MajorTopicYN="Y">Workflow</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34711713</ArticleId><ArticleId IdType="pmc">PMC8823905</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002202</ArticleId><ArticleId IdType="pii">00003453-202203000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bidwell SS, Merrell SB, Poles G, Morris AM; Synoptic Operative Report Study Group. Implementation of a synoptic operative report for rectal cancer: a mixed-methods study. Dis Colon Rectum. 2020;63:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">31914112</ArticleId></ArticleIdList></Reference><Reference><Citation>Casati B, Bjugn R. Structured electronic template for histopathology reporting on colorectal carcinoma resections: five-year follow-up shows sustainable long-term quality improvement. Arch Pathol Lab Med. 2012;136:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">22646273</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey A, Zhang H, Nixon J, Brown CJ. Comparison of data extraction from standardized versus traditional narrative operative reports for database-related research and quality control. Surgery. 2007;141:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">17560246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur I, Gur D, Recabaren JA. The computerized synoptic operative report: a novel tool in surgical residency education. Arch Surg. 2012;147:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21930975</ArticleId></ArticleIdList></Reference><Reference><Citation>Edhemovic I, Temple WJ, de Gara CJ, Stuart GC. The computer synoptic operative report&#x2013;a leap forward in the science of surgery. Ann Surg Oncol. 2004;11:941&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">15466354</ArticleId></ArticleIdList></Reference><Reference><Citation>Deal SB, D&#x2019;Angelica MI, Hawkins WG, et al. . Synoptic operative reporting for laparoscopic cholecystectomy and pancreaticoduodenectomy: a multi institutional pilot study evaluating completeness and surgeon perceptions. Am J Surg. 2018;216:935&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542551</ArticleId><ArticleId IdType="pubmed">29937324</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipps-Taylor M, Shortell SM. More than money: motivating physician behavior change in accountable care organizations. Milbank Q. 2016;94:832&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5192815</ArticleId><ArticleId IdType="pubmed">27995705</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquhart R, Porter GA, Sargeant J, Jackson L, Grunfeld E. Multi-level factors influence the implementation and use of complex innovations in cancer care: a multiple case study of synoptic reporting. Implement Sci. 2014;9:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173056</ArticleId><ArticleId IdType="pubmed">25224952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan BF, Jeyaraman MM, Mann AS, et al. . Behavior change interventions and policies influencing primary healthcare professionals&#x2019; practice-an overview of reviews. Implement Sci. 2017;12:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216570</ArticleId><ArticleId IdType="pubmed">28057024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubarsky DA, French MT, Gitlow HS, Rosen LF, Ullmann SG. Why money alone can&#x2019;t (always) &#x201c;nudge&#x201d; physicians: the role of behavioral economics in the design of physician incentives. Anesthesiology. 2019;130:154&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">30074931</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese M, Mejicano G, Xakellis G, Kokotailo P. Physician practice change I: a critical review and description of an Integrated Systems Model. Acad Med. 2009;84:1043&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakefield JG. Commitment to change: exploring its role in changing physician behavior through continuing education. J Contin Educ Health Prof. 2004;24:197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709559</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow SC, Morris AM, Baxter NN, et al. . Development of The American Society of Colon and Rectal Surgeons&#x2019; Rectal Cancer Surgery Checklist. Dis Colon Rectum. 2016;59:601&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902168</ArticleId><ArticleId IdType="pubmed">27270511</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters DH, Adam T, Alonge O, Agyepong IA, Tran N. Republished research: Implementation research: what it is and how to do it: implementation research is a growing but not well understood field of health research that can contribute to more effective public health and clinical policies and programmes. This article provides a broad definition of implementation research and outlines key principles for how to do it. Br J Sports Med. 2014;48:731&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">24659611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluijter CE, van Lonkhuijzen LR, van Slooten HJ, Nagtegaal ID, Overbeek LI. The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. Virchows Arch. 2016;468:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887530</ArticleId><ArticleId IdType="pubmed">27097810</ArticleId></ArticleIdList></Reference><Reference><Citation>Messenger DE, McLeod RS, Kirsch R. What impact has the introduction of a synoptic report for rectal cancer had on reporting outcomes for specialist gastrointestinal and nongastrointestinal pathologists? Arch Pathol Lab Med. 2011;135:1471&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">22032575</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranov NS, Nagtegaal ID, van Grieken NCT, et al. . Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports. Virchows Arch. 2019;475:255&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647878</ArticleId><ArticleId IdType="pubmed">31144018</ArticleId></ArticleIdList></Reference><Reference><Citation>Orah NO, Anunobi CC, Ojewola RW. Synoptic versus narrative reporting of prostate biopsies at a tertiary healthcare institution: challenges, successes and expectations. Sultan Qaboos Univ Med J. 2017;17:e319&#x2013;e323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642362</ArticleId><ArticleId IdType="pubmed">29062555</ArticleId></ArticleIdList></Reference><Reference><Citation>Srigley JR, McGowan T, Maclean A, et al. . Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol. 2009;99:517&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">19466743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankshear S, Srigley J, McGowan T, Yurcan M, Sawka C. Standardized synoptic cancer pathology reports &#x2013; so what and who cares? A population-based satisfaction survey of 970 pathologists, surgeons, and oncologists. Arch Pathol Lab Med. 2013;137:1599&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">23432456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy ED, Milot L, Fruitman M, et al. . Development and implementation of a synoptic MRI report for preoperative staging of rectal cancer on a population-based level. Dis Colon Rectum. 2014;57:700&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">24807594</ArticleId></ArticleIdList></Reference><Reference><Citation>Renshaw AA, Mena-Allauca M, Gould EW, Sirintrapun SJ. Synoptic reporting: evidence-based review and future directions. JCO Clin Cancer Inform. 2018;2:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873952</ArticleId><ArticleId IdType="pubmed">30652566</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquhart R, Jackson L, Sargeant J, Porter GA, Grunfeld E. Health system-level factors influence the implementation of complex innovations in cancer care. Healthc Policy. 2015;11:102&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729286</ArticleId><ArticleId IdType="pubmed">26742119</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu KM, Schoetz D. What impact might general surgery practice patterns of colon and rectal surgeons have on future training? Dis Colon Rectum. 2007;50:1250&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">17566827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34016825</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Treatment of Complex Idiopathic Fistula-in-Ano Using Autologous Centrifuged Adipose Tissue Containing Progenitor Cells: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1276</StartPage><EndPage>1285</EndPage><MedlinePgn>1276-1285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001924</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mesenchymal stem cells derived from adipose tissue have been successfully used to promote sphincter-saving anal fistula healing.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to evaluate the efficacy and safety of the use of autologous centrifuged adipose tissue in the healing process of cryptoglandular complex anal fistulas.</AbstractText><AbstractText Label="DESIGN">This is a randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a single center.</AbstractText><AbstractText Label="PATIENTS">Patients with complex perianal fistulas not associated with Crohn's disease were included. Rectovaginal fistulas were not included.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomly allocated to receive treatment with centrifuged adipose tissue injection (experimental group) and without injection (control group) in combination with fistula surgery.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was defined as the proportion of patients with complete fistula closure at 4 weeks (short-term outcome) and 6 months after surgery (long-term outcome). Healing was defined as when the external opening was closed with no perianal discharge on clinical assessment. The secondary outcome was safety that was evaluated by the analysis of adverse events up to 3 months after surgery. Pelvic MRI was performed at 3 months to assure safety and the accuracy of the clinical determination of healing. Postoperative pain, return to work/daily activities, persistent closure at 6 months, fecal incontinence, and patient satisfaction were evaluated.</AbstractText><AbstractText Label="RESULTS">Fifty-eight patients who received centrifuged adipose tissue injection and 58 patients who did not receive centrifuged adipose tissue injection were included in the safety and efficacy analysis. After 4 weeks, the healing rate was 63.8% in the experimental group compared with 15.5% in the control group (p &lt; 0.001). No major adverse events were recorded. Postoperative anal pain was significantly lower in the injection group. Time taken to return to work/daily activities was significantly shorter in the experimental group (3 days) than in the control group (17 days). At 6 months, persistent closure was similar in the 2 groups (86.2% vs 81%). Fecal Incontinence Score at 6 months after surgery was identical to the preoperative score. Patient satisfaction was high in both groups.</AbstractText><AbstractText Label="LIMITATIONS">The absence of blinding, the lack of correlation between stem cell content, and the clinical outcome were limitations of the study.</AbstractText><AbstractText Label="CONCLUSIONS">Autologous centrifuged adipose tissue injection may represent a safe, efficacious, and inexpensive option for the treatment of complex fistula-in-ano. See Video Abstract at http://links.lww.com/DCR/B607.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION">URL: https://www.clinicaltrials.gov. Identifier: NCT04326907.</AbstractText><AbstractText Label="EFICACIA Y SEGURIDAD DEL TRATAMIENTO DE LA FSTULA ANAL COMPLEJA IDIOPTICA UTILIZANDO TEJIDO ADIPOSO CENTRIFUGADO AUTLOGO QUE CONTIENE CLULAS PROGENITORAS UN ENSAYO CONTROLADO ALEATORIO">ANTECEDENTES:Las c&#xe9;lulas madre mesenquimales derivadas del tejido adiposo se han utilizado con &#xe9;xito para promover la curaci&#xf3;n de la f&#xed;stula anal con preservaci&#xf3;n de esf&#xed;nter.OBJETIVO:El objetivo de este estudio fue evaluar la eficacia y seguridad del uso de tejido adiposo aut&#xf3;logo centrifugado en el proceso de cicatrizaci&#xf3;n de f&#xed;stulas anales complejas de origen criptoglandular.DISE&#xd1;O:Ensayo controlado aleatorio.ENTORNO CL&#xcd;NICO:Estudio unic&#xe9;ntrico.PACIENTES:Se incluyeron pacientes con f&#xed;stulas perianales complejas no asociadas a Enfermedad de Crohn. No se incluyeron las f&#xed;stulas rectovaginales.INTERVENCIONES:Los pacientes fueron asignados aleatoriamente para recibir tratamiento con inyecci&#xf3;n de tejido adiposo centrifugado (grupo experimental) y sin inyecci&#xf3;n (grupo de control) en combinaci&#xf3;n con cirug&#xed;a de f&#xed;stula.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:El resultado primario se defini&#xf3; como la proporci&#xf3;n de pacientes con cierre completo de la f&#xed;stula a las 4 semanas (resultado a corto plazo) y 6 meses despu&#xe9;s de la cirug&#xed;a (resultado a largo plazo). La curaci&#xf3;n se defini&#xf3; cuando orificio externo se cerr&#xf3; sin secreci&#xf3;n perianal en la valoraci&#xf3;n cl&#xed;nica. El resultado secundario fue la seguridad que se evalu&#xf3; mediante el an&#xe1;lisis de los eventos adversos (EA) hasta 3 meses despu&#xe9;s de la cirug&#xed;a. La resonancia magn&#xe9;tica p&#xe9;lvica se realiz&#xf3; a los 3 meses para garantizar la seguridad y la precisi&#xf3;n cl&#xed;nica de la curaci&#xf3;n. Se evalu&#xf3; el dolor postoperatorio, el regreso al trabajo / actividades diarias, el cierre persistente a los 6 meses, la incontinencia fecal y la satisfacci&#xf3;n del paciente.RESULTADOS:Cincuenta y ocho pacientes que recibieron inyecci&#xf3;n de tejido adiposo centrifugado y 58 pacientes que no recibieron inyecci&#xf3;n de tejido adiposo centrifugado se incluyeron en el an&#xe1;lisis de seguridad y eficacia. Despu&#xe9;s de 4 semanas, la tasa de curaci&#xf3;n fue del 63,8% en el grupo experimental en comparaci&#xf3;n con el 15,5% en el grupo de control (p &lt;0,001). No se registraron eventos adversos importantes. El dolor anal posoperatorio fue significativamente menor en el grupo de inyecci&#xf3;n. El tiempo necesario para volver al trabajo / actividades diarias fue significativamente menor en el grupo experimental (3 d&#xed;as) con respecto al grupo de control (17 d&#xed;as). A los 6 meses, el cierre persistente fue similar en los dos grupos (86,2% vs 81%). La puntuaci&#xf3;n de incontinencia fecal a los 6 meses despu&#xe9;s de la cirug&#xed;a fue id&#xe9;ntica a la puntuaci&#xf3;n preoperatoria. La satisfacci&#xf3;n del paciente fue muy alta en ambos grupos.LIMITACIONES:Ausencia de cegamiento, falta de correlaci&#xf3;n entre el contenido de c&#xe9;lulas madre y el resultado cl&#xed;nico.CONCLUSIONES:La inyecci&#xf3;n de tejido adiposo centrifugado aut&#xf3;logo puede representar una opci&#xf3;n segura, eficaz y econ&#xf3;mica para el tratamiento de la f&#xed;stula anal compleja.Registro de ensayos cl&#xed;nicos: www.clinicaltrials.gov, identificador NCT04326907; No patrocinado.Consulte Video Resumen en http://links.lww.com/DCR/B607.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ascanelli</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamboni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section of Translational of Medicine and Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campioni</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Provincial Unique Laboratory Department, University Hospital Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grazia Sibilla</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chimisso</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zollino</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section of Translational of Medicine and Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valpiani</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Innovation Quality and Accreditation Unit, S. Anna University Hospital of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcoforo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Morphology, Surgery and Experimental Medicine, Section General Surgery, University of Ferrara, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04326907</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005242" MajorTopicYN="N">Fecal Incontinence</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="N">Rectal Fistula</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062707" MajorTopicYN="N">Return to Work</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34016825</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001924</ArticleId><ArticleId IdType="pii">00003453-202110000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Limura E, Giordano P. Modern management of anal fistula. World J Gastroenterol. 2015;21:12&#x2013;20.</Citation></Reference><Reference><Citation>van Onkelen RS, Gosselink MP, Schouten WR. Is it possible to improve the outcome of transanal advancement flap repair for high transsphincteric fistulas by additional ligation of the intersphincteric fistula tract? Dis Colon Rectum. 2012;55:163&#x2013;166.</Citation></Reference><Reference><Citation>Dudukgian H, Abcarian H. Why do we have so much trouble treating anal fistula? World J Gastroenterol. 2011;17:3292&#x2013;3296.</Citation></Reference><Reference><Citation>Gimble JM, Guilak F, Bunnell BA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther. 2010;1:19.</Citation></Reference><Reference><Citation>Garc&#xed;a-Olmo D, Garc&#xed;a-Arranz M, Herreros D, Pascual I, Peiro C, Rodr&#xed;guez-Montes JA. A phase I clinical trial of the treatment of Crohn&#x2019;s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416&#x2013;1423.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79&#x2013;86.</Citation></Reference><Reference><Citation>Aust L, Devlin B, Foster SJ, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. 2004;6:7&#x2013;14.</Citation></Reference><Reference><Citation>Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279&#x2013;4295.</Citation></Reference><Reference><Citation>Gimble JM, Bunnell BA, Guilak F. Human adipose-derived cells: an update on the transition to clinical translation. Regen Med. 2012;7:225&#x2013;235.</Citation></Reference><Reference><Citation>Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012;27:595&#x2013;600.</Citation></Reference><Reference><Citation>Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn&#x2019;s fistula. Stem Cells. 2013;31:2575&#x2013;2581.</Citation></Reference><Reference><Citation>Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn&#x2019;s fistula: a phase I clinical study. Cell Transplant. 2013;22:279&#x2013;285.</Citation></Reference><Reference><Citation>Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55:762&#x2013;772.</Citation></Reference><Reference><Citation>Choi S, Ryoo SB, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn&#x2019;s disease: a phase II clinical trial for safety and efficacy. Tech Coloproctol. 2017;21:345&#x2013;353.</Citation></Reference><Reference><Citation>Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2017;153:59&#x2013;62.e2.</Citation></Reference><Reference><Citation>Park KJ, Ryoo SB, Kim JS, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn&#x2019;s disease: a pilot clinical trial. Colorectal Dis. 2016;18:468&#x2013;476.</Citation></Reference><Reference><Citation>de la Portilla F, Alba F, Garc&#xed;a-Olmo D, Herrer&#xed;as JM, Gonz&#xe1;lez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn&#x2019;s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313&#x2013;323.</Citation></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Naldini G, Sturiale A, Fabiani B, Giani I, Menconi C. Micro-fragmented adipose tissue injection for the treatment of complex anal fistula: a pilot study accessing safety and feasibility. Tech Coloproctol. 2018;22:107&#x2013;113.</Citation></Reference><Reference><Citation>Norderval S, Lundby L, Hougaard H, Buntzen S, Weum S, de Weerd L. Efficacy of autologous fat graft injection in the treatment of anovaginal fistulas. Tech Coloproctol. 2018;22:45&#x2013;51.</Citation></Reference><Reference><Citation>Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2019;156:2208&#x2013;2216.e1.</Citation></Reference><Reference><Citation>Laureti S, Gionchetti P, Cappelli A, et al. Refractory complex Crohn&#x2019;s perianal fistulas: a role for autologous microfragmented adipose tissue injection. Inflamm Bowel Dis. 2020;26:321&#x2013;330.</Citation></Reference><Reference><Citation>Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum. 2011;54:1465&#x2013;1474.</Citation></Reference><Reference><Citation>Pu LLQ, Coleman SR, Cui X, Ferguson REH Jr, Vasconez HC. Autologous fat grafts harvested and refined by the Coleman technique: a comparative study. Plast Reconstr Surg. 2008;122:932&#x2013;937.</Citation></Reference><Reference><Citation>Zollino I, Campioni D, Sibilla MG, Tessari M, Malagoni AM, Zamboni P. A phase II randomized clinical trial for the treatment of recalcitrant chronic leg ulcers using centrifuged adipose tissue containing progenitor cells. Cytotherapy. 2019;21:200&#x2013;211.</Citation></Reference><Reference><Citation>Park SR, Kim JW, Jun HS, Roh JY, Lee HY, Hong IS. Stem cell secretome and its effect on cellular mechanisms relevant to wound healing. Mol Ther. 2018;26:606&#x2013;617.</Citation></Reference><Reference><Citation>Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy. 2016;18:13&#x2013;24.</Citation></Reference><Reference><Citation>Ceserani V, Ferri A, Berenzi A, et al. Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells. Vasc Cell. 2016;8:3.</Citation></Reference><Reference><Citation>Vezzani B, Shaw I, Lesme H, et al. Higher pericyte content and secretory activity of microfragmented human adipose tissue compared to enzymatically derived stromal vascular fraction. Stem Cells Transl Med. 2018;7:876&#x2013;886.</Citation></Reference><Reference><Citation>Ibatici A, Caviggioli F, Valeriano V, et al. Comparison of cell number, viability, phenotypic profile, clonogenic, and proliferative potential of adipose-derived stem cell populations between centrifuged and noncentrifuged fat. Aesthetic Plast Surg. 2014;38:985&#x2013;993.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33978329</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2386-5857</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias</Title><ISOAbbreviation>Emergencias</ISOAbbreviation></Journal><ArticleTitle>Thirty-day outcomes in frail older patients discharged home from the emergency department with acute heart failure: effects of high-risk criteria identified by the DEED FRAIL-AHF trial.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>173</EndPage><MedlinePgn>165-173</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES">To study the effect of high-risk criteria on 30-day outcomes in frail older patients with acute heart failure (AHF) discharged from an emergency department (ED) or an ED's observation and short-stay areas.</AbstractText><AbstractText Label="MATERIAL AND METHODS">Secondary analysis of discharge records in the Older AHF Key Data registry. We selected frail patients (aged &gt; 70 years) discharged with AHF from EDs. Risk factors were categorized as modifiable or nonmodifiable. The outcomes were a composite endpoint for a cardiovascular event (revisits for AHF, hospitalization for AHF, or cardiovascular death) and the number of days alive out-of-hospital (DAOH) within 30 days of discharge.</AbstractText><AbstractText Label="RESULTS">We included 380 patients with a mean (SD) age of 86 (5.5) years (61.2% women). Modifiable risk factors were identified in 65.1%, nonmodifiable ones in 47.8%, and both types in 81.6%. The 30-day cardiovascular composite endpoint occurred in 83 patients (21.8%). The mean 30-day DAOH observed was 27.6 (6.1) days. Highrisk factors were present more often in patients who developed the cardiovascular event composite endpoint: the rates for patients with modifiable, nonmodifiable, or both types of risk were, respectively, as follows in comparison with patients not at high risk: 25.0% vs 17.2%, P = .092; 27.6% vs 16.7%, P = .010; and 24.7% vs 15.2%, P = .098). The 30-day DAOH outcome was also lower for at-risk patients, according to type of risk factor present: modifiable, 26.9 (7.0) vs 28.4 (4.4) days, P = .011; nonmodifiable, 27.1 (7.0) vs 28.0 (5.0) days, P = .127; and both, 27.1 (6.7) vs 28.8 (3.4) days, P = .005). After multivariate analysis, modifiable risk remained independently associated with fewer days alive (adjusted absolute difference in 30-day DAOH, -1.3 days (95% CI, -2.7 to -0.1 days). Nonmodifiable factors were associated with increased risk for the 30-day cardiovascular composite endpoint (adjusted absolute difference, 10.4%; 95% CI, -2.1% to 18.7%).</AbstractText><AbstractText Label="CONCLUSION">Risk factors are common in frail elderly patients with AHF discharged home from hospital ED areas. Their presence is associated with a worse 30-day prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;n-S&#xe1;nchez</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario Cl&#xed;nico San Carlos, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Espa&#xf1;a. Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parra Esquivel</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario de Canarias, Tenerife, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llopis Garc&#xed;a</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario Cl&#xed;nico San Carlos, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Del Castillo</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario Cl&#xed;nico San Carlos, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Espa&#xf1;a. Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez Adrada</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Rey Juan Carlos, M&#xf3;stoles, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Unidad de Corta Estancia y Hospitalizaci&#xf3;n a Domicilio, Hospital General de Alicante, Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL-Fundaci&#xf3;n FISABIO), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez D&#xed;ez</LastName><ForeName>Mar&#xed;a Pilar</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Unidad de Corta Estancia, Hospital Universitario de Burgos, Burgos, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero Pareja</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario de Getafe, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzi Bordigoni</LastName><ForeName>Miguel Alberto</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Dur&#xe1;</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Unidad de Corta Estancia, Hospital La Fe, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibiano</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario Infanta Leonor, Vallecas, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Carles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguil&#xf3;</LastName><ForeName>Sira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Urgencias, Hospital Cl&#xed;nic, Barcelona, Grupo de Investigaci&#xf3;n "Urgencias: Procesos y Patolog&#xed;as", IDIBAPS, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n Mojarro</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital de Santa Tecla, Tarragona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Alfons</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital del Mar, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;era</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Reina Sof&#xed;a, Murcia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Picado</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n Cl&#xed;nica y Ensayos Cl&#xed;nicos, Hospital Cl&#xed;nico San Carlos, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorens</LastName><ForeName>Pere</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Unidad de Corta Estancia y Hospitalizaci&#xf3;n a Domicilio, Hospital General de Alicante, Instituto de Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de Alicante (ISABIAL-Fundaci&#xf3;n FISABIO), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>V&#xed;ctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Urgencias, Hospital Cl&#xed;nic, Barcelona, Grupo de Investigaci&#xf3;n "Urgencias: Procesos y Patolog&#xed;as", IDIBAPS, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital de Santa Tecla, Tarragona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez P&#xe9;rez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Preventiva, Hospital Cl&#xed;nico San Carlos; Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Facultad de Enfermer&#xed;a, Universidad de Enfermer&#xed;a, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Espa&#xf1;a. Servicio de Geriatr&#xed;a, Hospital Cl&#xed;nico San Carlos; Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Elpidio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Espa&#xf1;a. Servicio de Medicina Interna, Hospital Cl&#xed;nico San Carlos, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossell&#xf3;</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Health Research Institute of the Balearic Islands (IdISBa), Hospital Universitari Son Espases, Palma, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bueno</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario 12 de Octubre, Madrid, Espa&#xf1;a. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burillo</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias, Hospital Universitario de Canarias, Tenerife, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mir&#xf3;</LastName><ForeName>&#xd2;scar</ForeName><Initials>&#xd2;</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Urgencias, Hospital Cl&#xed;nic, Barcelona, Grupo de Investigaci&#xf3;n "Urgencias: Procesos y Patolog&#xed;as", IDIBAPS, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Registro OAK-Discharge y Estudio DEED FRAIL-AHF.</CollectiveName></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Resultados a 30 d&#xed;as en los pacientes mayores fr&#xe1;giles con insuficiencia cardiaca aguda dados de alta desde urgencias o sus unidades vinculadas que cumplen los criterios de alto riesgo del estudio DEED FRAIL-AHF.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Emergencias</MedlineTA><NlmUniqueID>9805751</NlmUniqueID><ISSNLinking>1137-6821</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Emergencias. 2021 Jun;33(3):161-162.</RefSource><PMID Version="1">33978327</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016330" MajorTopicYN="N">Frail Elderly</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="Y">Patient Discharge</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO">Estudiar el efecto a 30 d&#xed;as de los criterios de alto riesgo (CAR) en los mayores fr&#xe1;giles con insuficiencia cardiaca aguda (ICA) dados de alta desde urgencias o unidades vinculadas (URG_UV).</AbstractText><AbstractText Label="METODO">An&#xe1;lisis secundario del registro OAK-Discharge. Se seleccionaron pacientes fr&#xe1;giles 70 a&#xf1;os con ICA dados de alta desde URG_UV. Los CAR se clasificaron en modificables (CAR_M) y no modificables (CAR_NM). Las variables de resultado fueron la compuesta cardiovascular (VC_CV) (revisita u hospitalizaci&#xf3;n por ICA o mortalidad cardiovascular) y d&#xed;as vivos fuera del hospital (DVFH) a 30 d&#xed;as del alta.</AbstractText><AbstractText Label="RESULTADOS">Se incluyeron 380 pacientes con una edad media de 86 (DE 5,5) a&#xf1;os, 61,2% mujeres. Un 65,1% tuvo CAR_M, 47,8% CAR_NM y 81,6% ambos. Ochenta y tres pacientes (21,8%) presentaron la VC_CV a 30 d&#xed;as. La media de DVFH a 30 d&#xed;as fue de 27,6 (DE 6,1) d&#xed;as. La presencia de CAR modificable, no modificable o ambos, se asoci&#xf3; m&#xe1;s frecuentemente a la VC_CV a 30 d&#xed;as (25,0% vs 17,2%, p = 0,092; 27,6% vs 16,7%, p = 0,010; 24,7% vs 15,2%, p = 0,098) y a menos DVFH a 30 d&#xed;as [26,9 (7,0) vs 28,4 (4,4), p = 0,011; 27,1 (7,0) vs 28,0 (5,0), p = 0,127; 27,1 (6,7) vs 28,8 (3,4), p = 0,005], respectivamente. Tras el an&#xe1;lisis multivariante, los CAR_M se asociaron de forma independiente con menos DVFH a 30 d&#xed;as (diferencia absoluta ajustada &#x2013;1,3 d&#xed;as; IC 95% &#x2013;2,7 a &#x2013;0,1) y los CAR_NM con m&#xe1;s eventos en la VC_CV a 30 d&#xed;as (diferencia absoluta ajustada 10,4%; IC 95% 2,1% a 18,7%).</AbstractText><AbstractText Label="CONCLUSIONES">Los CAR son frecuentes en los mayores fr&#xe1;giles con ICA dados de alta desde URG_UV y su presencia se asocia a peores resultados a 30 d&#xed;as tras alta.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute heart failure.</Keyword><Keyword MajorTopicYN="N">Aged.</Keyword><Keyword MajorTopicYN="N">Anciano.</Keyword><Keyword MajorTopicYN="N">Emergency department.</Keyword><Keyword MajorTopicYN="N">Fragilidad.</Keyword><Keyword MajorTopicYN="N">Frail elderly.</Keyword><Keyword MajorTopicYN="N">Insuficiencia cardiaca aguda.</Keyword><Keyword MajorTopicYN="N">Servicio de urgencias.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33978329</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32496332</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Quality of Colonoscopy: A Comparison Between Gastroenterologists and Nongastroenterologists.</ArticleTitle><Pagination><StartPage>980</StartPage><EndPage>987</EndPage><MedlinePgn>980-987</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001659</ELocationID><Abstract><AbstractText Label="BACKGROUND">Colonoscopy performance by gastroenterologists has been shown to be associated with lower rates of developing interval colorectal cancer. However, it is unclear if this difference among specialists stems from a difference in meeting colonoscopy quality indicators.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study is to determine and compare the rates of colonoscopy quality indicators between different specialties.</AbstractText><AbstractText Label="DESIGN">This is a cohort study of patients undergoing screening colonoscopy investigating quality metrics as compared by the proceduralist specialty.</AbstractText><AbstractText Label="SETTING">All screening colonoscopies performed at the Cleveland Clinic between 2012 and 2014 were followed by manual chart review.</AbstractText><AbstractText Label="PATIENTS">Average-risk patients, &#x2265;50 years of age, who had a complete screening colonoscopy were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Adenoma detection rate, cecal intubation rate, withdrawal time, and other nonestablished overall and segment-specific rates were calculated and compared using t tests.</AbstractText><AbstractText Label="RESULTS">A total of 4151 patients were included in the analysis. Colonoscopies were performed by 54 (64.3%) gastroenterologists, 21 (25%) colorectal surgeons, and 9 (10.7%) general surgeons. Gastroenterologists had the highest overall adenoma detection rate (28.6&#x2009;&#xb1;&#x2009;1.2; p &lt; 0.001), followed by colorectal surgeons (24.3&#x2009;&#xb1;&#x2009;1.5) and general surgeons (18.4&#x2009;&#xb1;&#x2009;2.3), as well as the highest adenoma detection rate in men (34.7&#x2009;&#xb1;&#x2009;1.3; p &lt; 0.001), followed by colorectal surgeons (28.2&#x2009;&#xb1;&#x2009;1.6) and general surgeons (23.7&#x2009;&#xb1;&#x2009;2.6). Similarly, gastroenterologists had the highest adenoma detection rate in women (24.3&#x2009;&#xb1;&#x2009;1.1; p &lt; 0.001), followed by colorectal surgeons (21.6&#x2009;&#xb1;&#x2009;1.4) and general surgeons (12.9&#x2009;&#xb1;&#x2009;2.0). Withdrawal time was the longest among general surgeons (11.1&#x2009;&#xb1;&#x2009;5.5; p = 0.041), followed by colorectal surgeons (10.94&#x2009;&#xb1;&#x2009;5.2) and gastroenterologists (10.16&#x2009;&#xb1;&#x2009;1.26).</AbstractText><AbstractText Label="LIMITATIONS">We could not adjust for some procedure-related details such as retroflexion in the right colon and the use of end-of-scope devices.</AbstractText><AbstractText Label="CONCLUSIONS">In this study, only gastroenterologists met the currently accepted overall and sex-specific adenoma detection rate benchmarks. They also outperformed nongastroenterologists in many other nonestablished quality metrics. See Video Abstract at http://links.lww.com/DCR/B232.</AbstractText><AbstractText Label="CALIDAD DE LA COLONOSCOPIA">UNA COMPARACI&#xd3;N ENTRE GASTROENTER&#xd3;LOGOS Y NO GASTROENTER&#xd3;LOGOS: Se ha demostrado que el rendimiento de la colonoscopia por parte de los gastroenter&#xf3;logos, se asocia con tasas m&#xe1;s bajas de c&#xe1;ncer colorrectal en intervalos de desarrollo. Sin embargo, no est&#xe1; claro si esta diferencia entre especialistas, se deriva de una diferencia en el cumplimiento de los indicadores de calidad de la colonoscopia.El prop&#xf3;sito del estudio, es determinar y comparar las tasas de indicadores de calidad de colonoscopia entre diferentes especialidades.Este es un estudio de cohorte de pacientes sometidos a una colonoscopia de detecci&#xf3;n, que investiga m&#xe9;tricas de calidad en comparaci&#xf3;n con la especialidad de procesos.Todas las colonoscopias de detecci&#xf3;n realizadas en la Cl&#xed;nica Cleveland entre 2012 y 2014, fueron seguidas por una revisi&#xf3;n manual del expediente.Pacientes de riesgo promedio, &#x2265;50 a&#xf1;os de edad que se sometieron a una colonoscopia de detecci&#xf3;n completa.La tasa de detecci&#xf3;n de adenomas, tasa de intubaci&#xf3;n cecal, tiempo de retirada y otras tasas generales y espec&#xed;ficas de segmento no establecidas, se calcularon y compararon usando pruebas t.Un total de 4,151 pacientes fueron incluidos en el an&#xe1;lisis. Las colonoscopias fueron realizadas por 54 (64.3%) gastroenter&#xf3;logos, 21 (25%) cirujanos colorrectales y 9 (10.7%) cirujanos generales. Los gastroenter&#xf3;logos tuvieron la tasa de detecci&#xf3;n m&#xe1;s alta de adenomas en general (28.6&#x2009;&#xb1;&#x2009;1.2; p &lt; 0.001), seguidos por los cirujanos colorrectales (24.3&#x2009;&#xb1;&#x2009;1.5) y los cirujanos generales (18.4&#x2009;&#xb1;&#x2009;2.3), as&#xed; como la tasa de detecci&#xf3;n m&#xe1;s alta de adenoma en hombres (34.7&#x2009;&#xb1;&#x2009;1.3; p &lt; 0.001) seguido por cirujanos colorrectales (28.2&#x2009;&#xb1;&#x2009;1.6) y cirujanos generales (23.7&#x2009;&#xb1;&#x2009;2.6). Del mismo modo, los gastroenter&#xf3;logos tuvieron la tasa m&#xe1;s alta de detecci&#xf3;n de adenoma en mujeres (24.3&#x2009;&#xb1;&#x2009;1.1; p &lt; 0.001), seguidos por los cirujanos colorrectales (21.6&#x2009;&#xb1;&#x2009;1.4) y los cirujanos generales (12.9&#x2009;&#xb1;&#x2009;2.0). El tiempo de extracci&#xf3;n fue el m&#xe1;s largo entre los cirujanos generales (11.1&#x2009;&#xb1;&#x2009;5.5; p = 0.041) seguido por los cirujanos colorrectales (10.94&#x2009;&#xb1;&#x2009;5.2) y los gastroenter&#xf3;logos (10.16&#x2009;&#xb1;&#x2009;1.26).No pudimos ajustar algunos detalles relacionados con el procedimiento, tales como la retroflexi&#xf3;n en el colon derecho y el uso de accesorios endosc&#xf3;picos.En este estudio, solo los gastroenter&#xf3;logos cumplieron con los &#xed;ndices de referencia actualmente aceptados, de detecci&#xf3;n de adenomas en general y espec&#xed;ficas de g&#xe9;nero. Tambi&#xe9;n superaron a los no gastroenter&#xf3;logos en muchas otras m&#xe9;tricas no establecidas de calidad. Consulte Video Resumen en http://links.lww.com/DCR/B232. (Traducci&#xf3;n-Dr. Fidel Ruiz Healy).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muthukuru</LastName><ForeName>Sujit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alomari</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisen</LastName><ForeName>Ruchi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Malav P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Momani</LastName><ForeName>Laith</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talal Sarmini</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Biostatistics and Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muthukuru</LastName><ForeName>Shamant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Technology Management and Innovation, New York University, New York City, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thota</LastName><ForeName>Prashanthi N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanaka</LastName><ForeName>Madhusudhan R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D057405">Webcast</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2020 Jul;63(7):867-869. doi: 10.1097/DCR.0000000000001703.</RefSource><PMID Version="1">32496327</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Apr 1;64(4):e79. doi: 10.1097/DCR.0000000000001954.</RefSource><PMID Version="1">33496468</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Apr 1;64(4):e78. doi: 10.1097/DCR.0000000000001953.</RefSource><PMID Version="1">33496470</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Apr 1;64(4):e80. doi: 10.1097/DCR.0000000000001951.</RefSource><PMID Version="1">33496471</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Apr 1;64(4):e81-e82. doi: 10.1097/DCR.0000000000001952.</RefSource><PMID Version="1">33496480</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 May;64(5):e103. doi: 10.1097/DCR.0000000000001993.</RefSource><PMID Version="1">33939391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000236" MajorTopicYN="N">Adenoma</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072102" MajorTopicYN="N">Gastroenterologists</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019984" MajorTopicYN="N">Quality Indicators, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066231" MajorTopicYN="N">Surgeons</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496332</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001659</ArticleId><ArticleId IdType="pii">00003453-202007000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joseph DA, Meester RG, Zauber AG, et al. Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity. Cancer. 2016;122:2479&#x2013;2486.</Citation></Reference><Reference><Citation>Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M; Italian Multicentre Study Group. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001;48:812&#x2013;815.</Citation></Reference><Reference><Citation>Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977&#x2013;1981.</Citation></Reference><Reference><Citation>Rizk MK, Sawhney MS, Cohen J, et al. Quality indicators common to all GI endoscopic procedures. Gastrointest Endosc. 2015;81:3&#x2013;16.</Citation></Reference><Reference><Citation>Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2006;63(4 suppl):S16&#x2013;S28.</Citation></Reference><Reference><Citation>Yang MH, Cho J, Rampal S, et al. The association between cecal insertion time and colorectal neoplasm detection. BMC Gastroenterol. 2013;13:124.</Citation></Reference><Reference><Citation>Adler A, Wegscheider K, Lieberman D, et al. Factors determining the quality of screening colonoscopy: a prospective study on adenoma detection rates, from 12,134 examinations (Berlin colonoscopy project 3, BECOP-3). Gut. 2013;62:236&#x2013;241.</Citation></Reference><Reference><Citation>Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2015;81:31&#x2013;53.</Citation></Reference><Reference><Citation>Bretthauer M, Kaminski MF, L&#xf8;berg M, et al.; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial. JAMA Intern Med. 2016;176:894&#x2013;902.</Citation></Reference><Reference><Citation>Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370:1298&#x2013;1306.</Citation></Reference><Reference><Citation>Brenner H, Altenhofen L, Kretschmann J, et al. Trends in adenoma detection rates during the first 10 years of the German Screening Colonoscopy Program. Gastroenterology. 2015;149:356&#x2013;66.e1.</Citation></Reference><Reference><Citation>Digestive Health Network I. Medicare 100 Percent Research Identifiable Outpatient and Carrier Files, 2015. https://aspe.hhs.gov/system/files/pdf/255906/DHNAdditionalInfor.pdf. Accessed February 4, 2019.</Citation></Reference><Reference><Citation>Rabeneck L, Paszat LF, Saskin R. Endoscopist specialty is associated with incident colorectal cancer after a negative colonoscopy. Clin Gastroenterol Hepatol. 2010;8:275&#x2013;279.</Citation></Reference><Reference><Citation>Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007;132:96&#x2013;102.</Citation></Reference><Reference><Citation>Pace D, Borgaonkar M, Lougheed M, et al. Effect of colonoscopy volume on quality indicators. Can J Gastroenterol Hepatol. 2016;2016:2580894.</Citation></Reference><Reference><Citation>Bhangu A, Bowley DM, Horner R, Baranowski E, Raman S, Karandikar S. Volume and accreditation, but not specialty, affect quality standards in colonoscopy. Br J Surg. 2012;99:1436&#x2013;1444.</Citation></Reference><Reference><Citation>Hui AJ, Lau JY, Lam PP, et al. Comparison of colonoscopic performance between medical and nurse endoscopists: a non-inferiority randomised controlled study in Asia. Gut. 2015;64:1058&#x2013;1062.</Citation></Reference><Reference><Citation>Aronchick CA. Bowel preparation scale. Gastrointest Endosc. 2004;60:1037&#x2013;1038.</Citation></Reference><Reference><Citation>Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med. 2006;355:2533&#x2013;2541.</Citation></Reference><Reference><Citation>Kawamura T, Kawamura T, Oda Y, et al. Colonoscopy withdrawal time and adenoma detection rate: a Japanese multicenter analysis. J Gastroenterol Hepatol Res. 2017;6:2273&#x2013;2278.</Citation></Reference><Reference><Citation>Hsu CM, Lin WP, Su MY, Chiu CT, Ho YP, Chen PC. Factors that influence cecal intubation rate during colonoscopy in deeply sedated patients. J Gastroenterol Hepatol. 2012;27:76&#x2013;80.</Citation></Reference><Reference><Citation>Dominitz JA, Baldwin LM, Green P, Kreuter WI, Ko CW. Regional variation in anesthesia assistance during outpatient colonoscopy is not associated with differences in polyp detection or complication rates. Gastroenterology. 2013;144:298&#x2013;306.</Citation></Reference><Reference><Citation>Williams JE, Le TD, Faigel DO. Polypectomy rate as a quality measure for colonoscopy. Gastrointest Endosc. 2011;73:498&#x2013;506.</Citation></Reference><Reference><Citation>Williams JE, Holub JL, Faigel DO. Polypectomy rate is a valid quality measure for colonoscopy: results from a national endoscopy database. Gastrointest Endosc. 2012;75:576&#x2013;582.</Citation></Reference><Reference><Citation>Greene MA, Butterly LF, Goodrich M, et al. Matching colonoscopy and pathology data in population-based registries: development of a novel algorithm and the initial experience of the New Hampshire Colonoscopy Registry. Gastrointest Endosc. 2011;74:334&#x2013;340.</Citation></Reference><Reference><Citation>Singh S, Singh PP, Murad MH, Singh H, Samadder NJ. Prevalence, risk factors, and outcomes of interval colorectal cancers: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1375&#x2013;1389.</Citation></Reference><Reference><Citation>Leyden JE, Doherty GA, Hanley A, et al. Quality of colonoscopy performance among gastroenterology and surgical trainees: a need for common training standards for all trainees? Endoscopy. 2011;43:935&#x2013;940.</Citation></Reference><Reference><Citation>Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology. 2011;140:65&#x2013;72.</Citation></Reference><Reference><Citation>Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104&#x2013;117.</Citation></Reference><Reference><Citation>Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA. 2006;295:2366&#x2013;2373.</Citation></Reference><Reference><Citation>Baber J, Anusionwu C, Nanavaty N, Agrawal S. Anatomical distribution of colorectal cancer in a Veterans Affairs Medical Center. South Med J. 2014;107:443&#x2013;447.</Citation></Reference><Reference><Citation>Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107: dju427.</Citation></Reference><Reference><Citation>Pohl H, Robertson DJ, Mott LA, et al. Association between adenoma location and risk of recurrence. Gastrointest Endosc. 2016;84:709&#x2013;716.</Citation></Reference><Reference><Citation>Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795&#x2013;1803.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>